Bibliographic Details
| Title: |
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. |
| Authors: |
Chresta CM; AstraZeneca, Cheshire, United Kingdom. Christine.Chresta@astrazeneca.com, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M |
| Source: |
Cancer research [Cancer Res] 2010 Jan 01; Vol. 70 (1), pp. 288-98. Date of Electronic Publication: 2009 Dec 22. |
| Publication Type: |
Journal Article |
| Journal Info: |
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
